

Supporting Information

SI Figure 1




Supplementary Figure S1. (A) The body weight gain 1-12 weeks (g) and (B) quantity of food consumption (g) in control group, AOM group and Res-AOM group. *, p<0.05, compared to control group.

SI Figure 2




Supplementary Figure S2. Metabolic profiles depicted by PLS-DA scores plot of GC-TOFMS spectral data from the (A) colonic tissue (R2X = 0.286, R2Y = 0.923, Q2(cum) = 0.608), (B) serum (R2X = 0.453, R2Y = 0.918, Q2(cum) = 0.549), and (C) urine (R2X = 0.585, R2Y = 0.878, Q2(cum) = 0.661) of control group, AOM group and Res-AOM group.





Supplementary Figure S3. PLS-DA scores plots constructed with all the GC-TOFMS spectral features from colonic tissues (A and D), sera (B and E), and urine (C and F) of control group, AOM group and Res-AOM group.

SI Figure 4



Supplementary Figure S4. Disordered metabolism found in colon tissue, serum and urine. Red arrow and bar represents the variation in AOM group as compared to control group; Blue arrow and bar represents the variation in Res-AOM group as compared with AOM group; ↑means increased level; ↓means decreased level.